Taiwan is mapping out a four-year national pharmaceutical resilience preparedness program that aims to bolster the country’s domestic drug supply with a 24 billion new Taiwan dollar ($755 million) | ...

Olema Pharmaceuticals (OLMA) stock plummeted 41% after Roche's Phase 3 breast cancer trial failed its primary endpoint, ...

Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its ...

Ron Lanton, Senior Partner & Global Strategist, Lanton, Lanton & Sosa Law PLLC, discusses FDA’s removal of the two-trial requirement marking a significant policy shift and prompting sponsors to ...

Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation ZURICH, Switzerland, March 9, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX") (Nasdaq: ...

Key Takeaways. Section 804 creates a legal pathway for states and tribes to import certain Canadian prescription drugs, contingent on demonstrable consumer savings and adherence t ...

A new Ohio bill won't expand the 340B program, but it will protect patients' ability to fill prescriptions at their pharmacy of choice.

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2025 Earnings Call Transcript March 5, 2026 Atea Pharmaceuticals, Inc. misses on ...

Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals has dropped an early-stage candidate for advanced cancers from its ...

Q4 2025 earnings call: neffy sales, payer access expansion, DTC strategy, and 2026 outlook on adoption, SG&A discipline—read now.

Presented data at ESMO 2025 demonstrating promising efficacy with CRB-701 in head and neck squamous cell carcinoma (HNSCC) ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2025 Earnings Call Transcript March 5, 2026 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.07.